Objective: To provide a foundation to justify the presence of a full-time clinical pharmacist in the ambulatory cancer center in addition to an existing centralized pharmacist through cost avoidance calculation and patient and staff satisfaction surveys. Methods: The prospective, pilot study took place in an ambulatory cancer center over four weeks in 2014. Cost avoidance values were assigned to interventions performed by a pharmacy resident, who was present in the ambulatory cancer center during clinic hours, along with a centralized oncology pharmacist routinely working with the cancer center. Anonymous patient and staff satisfaction surveys based on a 5-point Likert scale were distributed to assess the perceived benefit of a pharmacist located in the ambulatory cancer center. Results: Data collection took place over approximately one month. After evaluation of 962 interventions from both pharmacists, the estimated cost avoidance was US$282,741 per pharmacist per year, yielding a net benefit of US$138,441. The most common interventions made by the resident included chemotherapy regimen review (n ¼ 290, 69%) and patient counseling (n ¼ 102, 24%), while the majority of the centralized pharmacist's interventions was chemotherapy regimen review (n ¼ 525, 97%). Results from the anonymous patient and staff surveys revealed an overall positive perception of the pharmacy resident while in the ambulatory cancer center. Conclusion: A full-time clinical pharmacist in an ambulatory cancer center is both financially beneficial and positively perceived by patients and staff.
Introduction
Clinical pharmacists are transforming today's healthcare environment by working closely with patients and providers in multidisciplinary teams in a variety of clinical areas, including oncology, to optimize patient care and achieve common goals. 1 Pharmacists play a key role in educating patients, incorporating evidence-based guidelines, and decreasing overall costs. 2 Drugs used in the oncology setting are some of the most expensive drugs on the market. In 2011, the National Institutes of Health predicted expenditures in oncology for diagnosis, treatment, and follow-up would reach 158 billion dollars. 3 Previous studies reporting pharmacists' involvement in the clinical setting have indicated an improved quality of care; however, in 2014, only 31.4% of hospitals had pharmacists practicing in ambulatory or primary care clinics. [4] [5] [6] There is a scarcity of articles relating to pharmacists' cost savings in the ambulatory oncology setting even though facilities have reported expanding clinical services into oncology clinics as early as the mid-1970s. 7 In the mid-1980s, two studies reported the implementation of pharmacy services in the area of oncology: one in an ambulatory cancer center and one in an inpatient oncology satellite pharmacy. While the major impact involved dispensing chemotherapy and other medications, it was noted that the clinical services of pharmacists were also sought out by the physicians and staff. 8, 9 The continuing trend away from traditional inpatient management of patients in hematology-oncology and to outpatient clinics allows for expanded roles for clinical pharmacists. 10 In the late 1990s, a prospective study evaluated the impact of a clinical pharmacist in an outpatient hematology-oncology clinic based on the percentage of interventions accepted by physicians. The acceptance rate was 94.8%, with the most frequent instances being patient counseling and therapeutic recommendations. One interesting finding in this study was that although the pharmacist was practicing in an ambulatory cancer center, the majority of interventions made (86.3%) were not chemotherapy related. 11 While these results reflect favorably upon clinical pharmacists in this position, the interventions made were not correlated to cost avoidance values in order to depict a financial impact. There seems to be a generally understood benefit of pharmacists in the oncology setting as many larger facilities and infusion clinics currently employ this type of pharmacy position; however, cost avoidance documentation is needed to reinforce this practice and gain support and funding from hospital administration.
The purpose of this pilot study was to provide a foundation to justify the presence of a full-time clinical pharmacist in the ambulatory cancer center in addition to an existing centralized pharmacist through cost avoidance calculation and patient and staff satisfaction surveys.
Methods
This prospective, observational pilot study took place over approximately four weeks during the pharmacy resident's oncology rotation from November to December 2014. The study gained Institutional Review Board approval in September 2014 and informed consent was waived. The ambulatory cancer center employs three hematology and oncology physicians and has approximately 12,000 patient visits per year (excluding patients presenting solely for laboratory test monitoring). Intervention quality assurance was provided by the study's research advisory panel, which consisted of clinical pharmacists.
Based on a needs assessment conducted prior to the beginning of the study period, a pharmacy resident was stationed in the treatment room, where patients presented for infusions lasting up to 8 h. The pharmacy resident also conducted a weekly chemotherapy education class for newly diagnosed patients instead of the nursing staff that traditionally facilitated this class.
Patients presenting to and staff employed by the ambulatory cancer center during the study period were included. Excluded populations were those under 18 years of age, over 65 years of age with cognitive disability, and patients who were incarcerated, in mental institutions, or pregnant. Interventions and the time per intervention made by the pharmacy resident and an oncology centralized pharmacist were documented and assigned to cost avoidance values based on previous literature (Table 1) . [12] [13] [14] Each intervention was assigned to a single category. When deciding which category to assign an intervention to, the intervention was classified as the most specific category appropriate. For example, a recommendation concerning antinausea medication for chemotherapy-related nausea would be classified as supportive care instead of as a therapeutic recommendation. Several aspects were considered when determining cost avoidance values to assign to various interventions; studies chosen were the most recent available and took place in either an oncology or ambulatory setting. Anonymous patient and staff surveys were distributed in order to evaluate patient and staff perceptions of having a pharmacist located in the ambulatory cancer center. Survey questions were modified from Delaney et al. 15 
Results

Interventions and cost avoidance
A total of 962 interventions were made during the study period. The pharmacy resident made 423 clinical interventions over 141 h with an acceptance rate of 100%. The centralized pharmacist made 539 interventions over 160 h with an acceptance rate greater than 95%. The two most frequent interventions by the pharmacy resident were chemotherapy regimen review (n ¼ 290, 69%) and patient counseling (n ¼ 102, 24%). The majority of the centralized pharmacist's interventions were chemotherapy regimen review (n ¼ 525, 97%) with additional activities consisting of order entry (n ¼ 1746). The centralized pharmacist provided direct oversight for complex therapy regimens including the preparation and distribution of chemotherapy to assure safety and timeliness. The average time documented per intervention was 20 min for the pharmacy resident and 17.8 min for the centralized pharmacist.
The cost avoidance values associated with the interventions made during the study period are shown in Table 1 . The cost of employing a pharmacist at the facility in which this study took place was calculated at US$69.38 per hour, including base pay plus benefits. When extrapolated to a 40-h work week with 52 weeks per year, the yearly cost of employing a pharmacist was estimated at US$144,300. Cost avoidance values when reported as benefit:cost ratio were determined as follows. First, cost per intervention type was obtained by multiplying the time per intervention type in minutes by the cost per minute of the pharmacist's salary (US$69.38 per hour divided by 60 min). Next, this cost per intervention type was multiplied by the benefit:cost ratio. For example, the benefit:cost ratio for drug information was 11.89:1, as cited by Schumock et al. 14 The documented time for the five drug information questions reported by the pharmacy resident was 25 min. Twenty-five minutes Â cost of a pharmacist per minute Â 11.89 ¼ US$344 (see Table 1 ).
Cost avoidance was calculated per hour and extrapolated to a yearly estimate for both pharmacists based on a 40-h work week with 52 weeks per year. The cost avoidance during the study period for the pharmacy resident was US$22,416 over 141 h spent in the clinic, which was US$330,676 when extrapolated to a 40-h work week with 52 weeks per year (US$22,416 7 141 h Â 40 h per week Â 52 weeks per year). The centralized pharmacist's interventions resulted in a cost avoidance of US$18,062 over 160 h, which was US$234,806 when extrapolated to a 40-h work week with 52 weeks per year. The combined average yearly cost avoidance was US$565,482, which is US$282,741 per pharmacist. When the cost of employing a pharmacist was subtracted from the average yearly cost avoidance per pharmacist, this yielded a net benefit of US$138,441, further validating the financial benefit of employing a clinical pharmacist in the ambulatory cancer center.
Satisfaction survey results
Although patients often had multiple encounters in the clinic, anonymous satisfaction surveys were distributed to patients only after their first encounter with the pharmacy resident. Completed surveys were turned in at the check-out desk. Thirty-two patients received the survey. There was a 25% response rate with 100% of the responses being positive (Table 2 ). Staff surveys were Chemotherapy regimen review was defined per Calloway et al. 13 as review of chemotherapy protocols, doses, dose adjustments, calculations, cumulative doses, etc. Additional categories were utilized when other interventions were made as a result of this review. also overwhelmingly positive (Table 3) . Seven out of eight nurses and one out of three physicians returned the anonymous survey.
Discussion
This study found that pharmacists have a positive impact on patient care in an ambulatory cancer center setting. An estimated yearly cost avoidance per pharmacist of US$282,741 with a net benefit of US$138,441 and overwhelmingly positive survey results indicate not only financial benefits but also patient satisfaction. As demonstrated in this study, pharmacists can make a wide array of interventions to benefit the patient, institution, and other staff.
Some interventions were not associated with cost avoidance values due to either a scarcity of data in published literature (see Table 1 ) or intangible benefits such as patient and staff satisfaction. Based on the comments from the surveys, patients appreciated the focused medication counseling and reassurance the pharmacist provided. The staff appreciated the readily accessible medication expert that saved them valuable time. The pharmacist-led patient medication counseling also removed this responsibility from nursing staff.
To the best of our knowledge, this is the first observational study detailing the cost avoidance of pharmacists in an ambulatory cancer center. Based on previous literature, pharmacists in the ambulatory cancer setting have been shown to be beneficial. 1, 7, 8, 11, [16] [17] [18] [19] [20] [21] A descriptive report detailing the development of clinical pharmacy services in a North Carolina outpatient oncology clinic was published in 2011. 1 Interventions such as patient counseling and supportive care recommendations were similar to those demonstrated in this study; however, a Board Certified Oncology Pharmacist was utilized and interventions were not associated with cost avoidance values. Similarly, a case study published in 2011 discussed the implementation of an oncology pharmacist specialist at an outpatient infusion center. 16 Responsibilities for this position included working with an oncology clinical nurse specialist to develop policies and procedures as well as train additional pharmacists to be proficient in the oncology clinic. A 45% reduction in errors such as incorrect dose, incorrect schedule, and missed premedication was observed with the implementation of pharmacy services, but no cost avoidance values were reported. Another prospective interventional study in an ambulatory cancer center in Singapore was published in 2015. 17 Pharmacist interventions had a 93% acceptance rate over a two-month period, but the authors stated that little is known about the impact of cost savings and that more studies need to assess the pharmacoeconomic impact of pharmacists' interventions. These papers support this study's findings of the benefit of a pharmacist in the ambulatory oncology setting and the need for assessment of cost savings.
Patient satisfaction survey results in this study were overwhelmingly positive and consistent with published data. A study conducted in a NeuroOncology clinic focused on the impact a pharmacist can have in regard to decreasing the anxiety and apprehension felt by patients who came into the clinic. 15 Patient surveys that were returned indicated 100% of patients felt they obtained useful information from the pharmacist, 90% felt the pharmacist should be integrated in to the Staff survey, N ¼ 8 The pharmacist interacted with the staff in a way that was beneficial.
(2-5)
Pharmacist was resourceful and available to answer drug information questions.
(4-5)
Presence of a pharmacist had a positive impact and improved outcomes related to patients.
(3-5)
I used the pharmacist as a resource more often when present in the clinic.
(1-5)
The pharmacist is able to make appropriate recommendations/interventions.
(2-5)
Presence of a pharmacist allowed the clinic to run more efficiently
I feel the presence of a pharmacist in the clinic full time would be valuable.
(2-5) a
The Likert scale is a five point scale with 1 ¼ strongly disagree, 2 ¼ disagree, 3 ¼ neither agree nor disagree, 4 ¼ agree, 5 ¼ strongly agree. 
(4-5)
The pharmacist spent enough time with me. 5 (4-5) The recommendations by the pharmacist were beneficial.
The pharmacist was able to answer my questions in a way that was helpful.
(5-5)
The pharmacist improved my experience at the ambulatory cancer center.
The Likert scale is a five point scale with 1 ¼ strongly disagree, 2 ¼ disagree, 3 ¼ neither agree nor disagree, 4 ¼ agree, 5 ¼ strongly agree.
NeuroOncology team, and many commented that they felt more supported and less rushed through the process. In a separate study at a community oncology clinic, a survey tool was developed to assess patients' perspectives of pharmacists. 2 It was found that 98% of patients agreed information provided by the pharmacist was helpful, and 97% indicated questions were answered in a way that met the patients' expectations. Positive feedback from patient surveys is significant as it can affect reimbursement rates. Hospital Consumer Assessment of Healthcare Providers and Systems scores are increasingly reported, reinforcing this trend.
Limitations of this study included limited pharmacy resident experience in the hematology/oncology setting, which led to additional time spent researching information pertaining to specific drug regimens and drug information questions. Since the pharmacy resident was located in the infusion room, patients presenting to the clinic only for physician visits were not seen. A pharmacist could potentially impact these patients as well, as some may be on oral treatment regimens that do not require a visit in the infusion room. Another limitation was the abbreviated time frame. Given that this was a prospective pilot study, the time frame was one month during the pharmacy resident's oncology rotation, which was then extrapolated to one year to calculate cost avoidance totals. Additionally, there was limited data associating cost avoidance values to interventions. This resulted in cost avoidance values not being available for every intervention, which may have led to an underestimation of total cost avoidance. Finally, an acceptance rate of 100% for the pharmacy resident and greater than 95% for the centralized pharmacist may indicate a need for more aggressive recommendations which would increase the total number of interventions and show further cost avoidance.
Conclusion
By averaging the cost avoidance from both pharmacists, this study estimated a cost avoidance of US$282,741 per pharmacist per year, yielding a net benefit of US$138,441. Additionally, anonymous survey data indicated that patients and staff viewed the presence of a full-time pharmacist located in the ambulatory cancer center as advantageous. A fulltime clinical pharmacist in an ambulatory cancer center is both financially beneficial and positively perceived by patients and staff.
